CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Roche has signed a definitive agreement to acquire Kapa Biosystems, a privately held company that employs proprietary technologies to optimize enzymes for next-generation sequencing as well as polymerase chain reaction and real-time PCR applications.
Kapa’s proprietary protein engineering technology allows for the generation and screening of large numbers of enzyme variants. Tailored enzymes with improved performance for specific applications can be rapidly selected, expediting product development timelines. Wilmington, Mass.-based Kapa has a portfolio of NGS reagents that includes enzymes such as novel DNA polymerases, with the potential to improve the performance of the entire sequencing workflow.
Roche Diagnostics, 800-428-5074